Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
February 6, 2018 6:51 AM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $52.00) while maintaining a Underperform rating.
Arfaei commented, "When the dust finally settles with the 1L-NSCLC data, we see a fragmented market with Merck's Keytruda... More
Bristol-Myers Squibb (BMY) Reports Pivotal Phase 3 CheckMate-227 Study Provides Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination
February 5, 2018 7:09 AM ESTBristol-Myers Squibb Company (NYSE: BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survival (PFS) with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients whose tumors have high (10 mutations/megabase, mut/mb) tumor mutation burden (TMB),... More
